Discover

News & Info

Trade

LongbridgeAI

Quote List Quote List

Ascendis Pharmac(ASND.US)

Event Tracking

Apr9

FactSet analysts lower EPS estimates for Ascendis Pharma in 2026

14:21

Apr8

Ascendis Pharmaceuticals Announces Positive Data from COACH Trial of Dual Therapy for Osteogenesis Imperfecta in Children

12:18

Apr6

Ascendis Pharma's Yuviwel Receives Orphan Drug Designation from FDA and Gets Listed for Sale

20:14

Mar17

Ascendis Pharmaceuticals Announces Results of TransCon hGH Phase 2 Trial

12:34

Mar16

Ascendis Pharmaceuticals Reports Latest Trial Data on TransCon CNP for Osteogenesis Imperfecta

12:03

Mar5

Ascendis Pharma Plans to Launch New Therapy YUVIWEL in 2024

03:33

Schedules & Filings

Schedules

Filings

Feb11

Earning Release(EST)

FY2025 Q4 Earning Release (USD) Revenue 290.7 M, Net Income -39.42 M, EPS -0.6459

Nov12

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 250.54 M, Net Income -71.52 M, EPS -1.1772

Aug7

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 185 M, Net Income -45.48 M, EPS -0.7523

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

Ascendis Pharmac(ASND.US)

Ascendis Pharmac Stock Performance Chart